Cardlytics (CDLX) PT Lowered to $120 at Needham & Company on Slower Than Expected Recovery

August 4, 2021 6:55 AM EDT Send to a Friend
Needham & Company analyst Kyle Peterson lowered the price target on Cardlytics (NASDAQ: CDLX) to $120.00 (from $135.00) after 2Q ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login